NASDAQ: NRXPNrx Pharmaceuticals Inc Stock
$3.14+0.02 (+0.64%)
Updated Apr 25, 2024
NRXP Price
$3.14
Fair Value Price
-$0.60
Market Cap
$30.05M
52 Week Low
$2.21
52 Week High
$12.00
P/E
-0.79x
P/B
-2.56x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$30.15M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.62
Operating Cash Flow
-$22M
Beta
0.46
Next Earnings
May 14, 2024
Ex-Dividend
N/A
Next Dividend
N/A
NRXP Overview
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NRXP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NRXP ($3.14) is overvalued by 621.01% relative to our estimate of its Fair Value price of -$0.60 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NRXP ($3.14) is not significantly undervalued (621.01%) relative to our estimate of its Fair Value price of -$0.60 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NRXP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NRXP due diligence checks available for Premium users.
Be the first to know about important NRXP news, forecast changes, insider trades & much more!
NRXP News
Valuation
NRXP fair value
Fair Value of NRXP stock based on Discounted Cash Flow (DCF)
Price
$3.14
Fair Value
-$0.60
Undervalued by
621.01%
NRXP ($3.14) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NRXP ($3.14) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NRXP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NRXP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.79x
Industry
15.41x
Market
40.97x
NRXP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-2.56x
Industry
5.8x
NRXP's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.3M
Profit Margin
0%
NRXP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$7.3M
Liabilities
$19.0M
Debt to equity
-1.62
NRXP's short-term liabilities ($19.05M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NRXP's short-term assets ($6.88M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NRXP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NRXP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.2M
Investing
$1.0k
Financing
-$1.1M
NRXP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NRXP vs Biotech Stocks
Nrx Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.